The board of directors of biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share of the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
Shareholders of record at the close of business as of 16 March 2020 will receive the dividend on 7 April 2020.
Merck said that for more than a century, it has been providing medicines and vaccines for the most challenging diseases.
The company delivers innovative health solutions such as prescription medicines, vaccines, biologic therapies and animal health products. It operates in more than 140 countries.
Inspiration Healthcare secures US purchasing agreement to drive Airon growth
West to sell SmartDose 3.5mL On-Body Delivery System rights to AbbVie for USD112.5m
Citius Pharmaceuticals reports full-year financial results
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Amgen announces Q1 2026 dividend
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera